文献速递胸部肿瘤

Sevabertinib:一种对肺癌有活性的可逆性HER2抑制剂

Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.
PubMed 文献 · Cancer Discov · 2026-01-01

本文报道可逆性EGFR-HER2双重抑制剂Sevabertinib(BAY 2927088)在携带HER2外显子20插入、点突变及野生型ERBB2扩增的肺癌模型中的临床前活性,并展示其对神经调节蛋白-1融合依赖细胞系的活性;I/II期临床试验初步显示HER2突变肺癌患者可能获益。

要点

  • Sevabertinib对HER2外显子20插入等激活突变肺癌模型有临床前活性。
  • I/II期试验早期数据显示HER2突变肺癌患者可能获益。
  • 该药为可逆性EGFR-HER2双重抑制剂,对野生型EGFR具有选择性。

核心结论

  • Sevabertinib在携带HER2外显子20插入等激活突变的肺癌临床前模型中显示活性,I/II期试验早期患者反应提示HER2突变肺癌潜在获益。

研究设计与样本

  • 临床前研究评估Sevabertinib在携带HER2外显子20插入、点突变及野生型ERBB2扩增的肺癌模型中的活性,并报告I/II期临床试验患者反应。

主要发现

  • Sevabertinib在携带HER2外显子20插入、点突变及野生型ERBB2扩增的肺癌模型中显示临床前活性。
  • Sevabertinib在依赖神经调节蛋白-1融合的癌细胞系中显示活性。
  • I/II期临床试验报告HER2突变肺癌患者对Sevabertinib的治疗反应。

关键数值与推荐

  • HER2外显子20插入及其他激活突变发生于2%至4%的肺腺癌。

临床怎么用

  • 对于HER2激活突变(包括外显子20插入)的肺癌患者,Sevabertinib可能提供新的治疗选择。

局限性

  • I/II期临床试验数据为早期结果,样本量与疗效阈值未在摘要中报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Exon 20 insertions of HER2, encoded by erb-b2 receptor tyrosine kinase 2 (ERBB2), and other activating HER2 mutations occur in 2% to 4% of lung adenocarcinomas, but there are only limited therapeutic options available for these patients. Sevabertinib (BAY 2927088) is a potent and reversible dual EGFR-HER2 inhibitor that is selective with respect to wild-type EGFR. In this study, we report the preclinical activity of sevabertinib in lung cancer models harboring alterations of HER2, including exon 20 insertions, point mutations, and amplification of wild-type ERBB2. We furthermore demonstrate the activity of sevabertinib in a cancer cell line dependent on a fusion of neuregulin-1, a ligand for the HER2 family member and heterodimerization partner, HER3. Finally, we report patient responses to sevabertinib from a phase 1/2 clinical trial, indicating potential benefit for patients with HER2-mutant lung cancer. SIGNIFICANCE: Additional therapeutic options are needed for patients with lung cancer with HER2 activating mutations, including exon 20 insertions. Sevabertinib shows activity against ERBB2-encoded HER2 exon 20 insertions in preclinical models of lung cancer, corroborated by early data from a phase 1/2 clinical trial.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Siegel F, Siegel S, Kotýnková K, et al. Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer Discov. 2026. PMID: 41090369. doi:10.1158/2159-8290.CD-25-0605

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。